BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 3, Pages 649-657
Publisher
Springer Nature
Online
2013-11-25
DOI
10.1038/leu.2013.358
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Proposal Regarding Reporting of In Vitro Testing Results
- (2013) M. A. Smith et al. CLINICAL CANCER RESEARCH
- Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
- (2013) S E M Herman et al. LEUKEMIA
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- New Strategies in the Treatment of Mantle Cell Lymphoma
- (2012) C. Deng et al. CLINICAL CANCER RESEARCH
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
- (2012) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- SYK inhibition and response prediction in diffuse large B-cell lymphoma
- (2011) S. Cheng et al. BLOOD
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals
- (2011) Alison M. MCCaig et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2011) P. C. Amrein et al. CLINICAL CANCER RESEARCH
- Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia
- (2010) Mariana Serpa et al. ACTA HAEMATOLOGICA
- Early Events in B Cell Activation
- (2010) Naomi E. Harwood et al. Annual Review of Immunology
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
- (2010) M. Suljagic et al. BLOOD
- PI3K/p110 is a novel therapeutic target in multiple myeloma
- (2010) H. Ikeda et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
- (2010) M. Buchner et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Activities of SYK and PLC 2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib
- (2010) Z. Song et al. CLINICAL CANCER RESEARCH
- Aggressive Lymphomas
- (2010) Georg Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B Cell Signaling and Fate Decision
- (2009) Tomohiro Kurosaki et al. Annual Review of Immunology
- In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia
- (2009) C. Calissano et al. BLOOD
- B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
- (2009) M. P. Quiroga et al. BLOOD
- Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
- (2009) A. V. Kurtova et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles
- (2009) M Plander et al. LEUKEMIA
- The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes
- (2008) A. Veldurthy et al. BLOOD
- Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro
- (2008) Lilian Amrein et al. BRITISH JOURNAL OF HAEMATOLOGY
- Novel Insights in Chronic Lymphocytic Leukemia: Are We Getting Closer to Understanding the Pathogenesis of the Disease?
- (2008) Federico Caligaris-Cappio et al. JOURNAL OF CLINICAL ONCOLOGY
- Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma
- (2008) P Lu et al. LEUKEMIA
- Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib
- (2008) C Yang et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started